{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:31:23Z","timestamp":1790872283733,"version":"4.1.0"},"publisher-location":"Chichester, UK","reference-count":85,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd004246.pub3","type":"reference-entry","created":{"date-parts":[[2010,11,29]],"date-time":"2010-11-29T19:43:41Z","timestamp":1291059821000},"source":"Crossref","is-referenced-by-count":17,"title":["Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-na\u00efve individuals"],"prefix":"10.1002","author":[{"given":"Lawrence CE","family":"Mbuagbaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H","family":"Irlam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicen","family":"Spaulding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandi","family":"Siegfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,12,8]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD004246.pub3-BIB1|cit1","first-page":"24","article-title":"[Nevirapine or efavirenz in combination with two nucleoside analogues in HIV-infected antiretroviral-naive patients]","volume":"20","author":"Gaytan","year":"2004","journal-title":"Medicina Interna de Mexico"},{"issue":"12","key":"10.1002\/14651858.CD004246.pub3-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1086\/599114","article-title":"A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study","volume":"48","author":"Manosuthi","year":"2009","journal-title":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"},{"issue":"3","key":"10.1002\/14651858.CD004246.pub3-BIB3|cit3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1310\/0CJ5-2ABQ-CB00-6MR6","article-title":"SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals","volume":"3","author":"Nunez","year":"2002","journal-title":"HIV Clinical Trials"},{"key":"10.1002\/14651858.CD004246.pub3-BIB4|cit4","series-title":"XVI International AIDS Conference","article-title":"Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]","author":"Sow"},{"key":"10.1002\/14651858.CD004246.pub3-BIB5|cit5","series-title":"16 th Conference on Retroviruses and Opportunistic Infections","article-title":"Once-daily Nevirapine vs Efavirenz in the Treatment of HIV-infected Patients with TB: A Randomized Clinical Trial","author":"Swaminathan"},{"issue":"5","key":"10.1002\/14651858.CD004246.pub3-BIB6|cit6","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1310\/hct0905-324","article-title":"Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons","volume":"9","author":"Berg-Wolf","year":"2008","journal-title":"HIV Clinical Trials"},{"issue":"9417","key":"10.1002\/14651858.CD004246.pub3-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study","volume":"363","author":"Leth","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD004246.pub3-BIB8|cit8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAD.0b013e3282f3cc35","article-title":"Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA","volume":"22","author":"Bannister","year":"2008","journal-title":"AIDS (London, England)"},{"key":"10.1002\/14651858.CD004246.pub3-BIB9|cit9","first-page":"343","article-title":"Hepatotoxicity in patients prescribed efavirenz or nevirapine","volume":"13","author":"Bruck","year":"2008","journal-title":"European Journal of Medical Research"},{"issue":"6","key":"10.1002\/14651858.CD004246.pub3-BIB10|cit10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1089\/aid.2007.0295","article-title":"Long-Term Efficacy and Tolerance of Efavirenz- and Nevirapine-Containing Regimens in Adult HIV Type 1 Senegalese Patients","volume":"24","author":"Beaudrap","year":"2008","journal-title":"AIDS Research and Human Retroviruses"},{"key":"10.1002\/14651858.CD004246.pub3-BIB11|cit11","first-page":"760","article-title":"Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China","volume":"85","author":"Han","year":"2005","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"6","key":"10.1002\/14651858.CD004246.pub3-BIB12|cit12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1258\/0956462054094060","article-title":"Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort)","volume":"16","author":"Hartmann","year":"2005","journal-title":"International Journal of STD & AIDS"},{"issue":"9","key":"10.1002\/14651858.CD004246.pub3-BIB13|cit13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00105-005-0911-z","article-title":"Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz","volume":"56","author":"Hartmann","year":"2005","journal-title":"Hautarzt"},{"key":"10.1002\/14651858.CD004246.pub3-BIB14|cit14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1258\/0956462054094060","article-title":"Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort)","volume":"16","author":"Hartmann","year":"2005","journal-title":"International Journal of STD & AIDS"},{"issue":"6","key":"10.1002\/14651858.CD004246.pub3-BIB15|cit15","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ijid.2007.10.008","article-title":"Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children","volume":"12","author":"Lapphra","year":"2008","journal-title":"International Journal of Infectious Diseases : IJID : official publication of the International Society for Infectious Diseases"},{"key":"10.1002\/14651858.CD004246.pub3-BIB16|cit16","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00126334-200404150-00007","article-title":"Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study","volume":"35","author":"Manfredi","year":"2004","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1002\/14651858.CD004246.pub3-BIB17|cit17","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1310\/EWWC-YLJ6-8LHE-054A","article-title":"Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine","volume":"6","author":"Manfredi","year":"2005","journal-title":"HIV Clinical Trials"},{"key":"10.1002\/14651858.CD004246.pub3-BIB18|cit18","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1097\/QAD.0b013e3280110cae","article-title":"Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells\/microl","volume":"20","author":"Manfredi","year":"2006","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD004246.pub3-BIB19|cit19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1468-1293.2004.00195.x","article-title":"Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection","volume":"5","author":"Manosuthi","year":"2004","journal-title":"HIV Medicine"},{"key":"10.1002\/14651858.CD004246.pub3-BIB20|cit20","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1097\/QAD.0b013e328310407e","article-title":"Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults","volume":"22","author":"Nachega","year":"2008","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD004246.pub3-BIB21|cit21","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/135965350400900602","article-title":"Alteration of antiretroviral drug regimens for HIV infection: Efficacy, safety and tolerability at week 96 of the Swatch Study","volume":"9","author":"Negredo","year":"2004","journal-title":"Antiviral Therapy"},{"issue":"3","key":"10.1002\/14651858.CD004246.pub3-BIB22|cit22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/INF.0b013e31818dd72b","article-title":"Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less","volume":"28","author":"Puthanakit","year":"2009","journal-title":"The Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD004246.pub3-BIB23|cit23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/INF.0b013e318194eea6","article-title":"Pattern and predictors of immunologic recovery in Human Immunodeficiency Virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy","volume":"28","author":"Puthanakit","year":"2009","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"4","key":"10.1002\/14651858.CD004246.pub3-BIB24|cit24","first-page":"287","article-title":"NNRTI data in naive patients","volume":"21","author":"Anonymous","year":"2007","journal-title":"AIDS Patient Care and STDS"},{"key":"10.1002\/14651858.CD004246.pub3-BIB25|cit25","series-title":"International Conference on AIDS","first-page":"abstract no. B1","article-title":"Final analysis of a prospective, randomized, open-label, multicentre trial in naive, HIV-1-infected patients, comparing ZDV\/3TC vs d4T\/ddI, plus Efavirenz, Nevirapine or Indinavir\/Ritonavir (AMADEUS 01 study)","author":"Antela"},{"key":"10.1002\/14651858.CD004246.pub3-BIB26|cit26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00002030-200501280-00011","article-title":"Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine,efavirenz or both drugs","volume":"19","author":"Ananworanich","year":"2005","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD004246.pub3-BIB27|cit27","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/QAI.0b013e3181a56e81","article-title":"The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals","volume":"51","author":"Annan","year":"2009","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1002\/14651858.CD004246.pub3-BIB28|cit28","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/427216","article-title":"Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection","volume":"40","author":"Aranzabal","year":"2005","journal-title":"Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America"},{"key":"10.1002\/14651858.CD004246.pub3-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1177\/135965350701200811","article-title":"Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy","volume":"12","author":"Aurpibul","year":"2007","journal-title":"Antiviral Therapy"},{"key":"10.1002\/14651858.CD004246.pub3-BIB30|cit30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1258\/ijsa.2007.007236","article-title":"Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002)","volume":"19","author":"Beck","year":"2008","journal-title":"International Journal of STDs and AIDS"},{"key":"10.1002\/14651858.CD004246.pub3-BIB31|cit31","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-150-10-200905190-00117","article-title":"The President's Emergency Plan for AIDS Relief in Africa: an evaluation of outcomes","volume":"150","author":"Bendavid","year":"2009","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD004246.pub3-BIB32|cit32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1086\/524080","article-title":"Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection","volume":"46","author":"Berenguer","year":"2008","journal-title":"Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"4","key":"10.1002\/14651858.CD004246.pub3-BIB33|cit33","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1046\/j.1464-2662.2001.00083.x","article-title":"Guidelines for the treatment of HIV-infected adults with antiretroviral therapy","volume":"2","year":"2001","journal-title":"HIV Medicine"},{"key":"10.1002\/14651858.CD004246.pub3-BIB34|cit34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/135965350701200508","article-title":"Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort","volume":"12","author":"Boulle","year":"2007","journal-title":"Antiviral Therapy"},{"key":"10.1002\/14651858.CD004246.pub3-BIB35|cit35","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/jama.300.5.530","article-title":"Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when co-administered with rifampicin-based antitubercular therapy","volume":"300","author":"Boulle","year":"2008","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD004246.pub3-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/QAD.0b013e3281532b31","article-title":"Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies","volume":"21","author":"Braithwaite","year":"2007","journal-title":"AIDS"},{"issue":"RR-7","key":"10.1002\/14651858.CD004246.pub3-BIB37|cit37","first-page":"1","article-title":"Recommendations of the Panel on Clinical Practices for Treatment of HIV","volume":"51","year":"2002","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"1","key":"10.1002\/14651858.CD004246.pub3-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2007.00426.x","article-title":"Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review","volume":"8","author":"Cooper","year":"2007","journal-title":"HIV Medicine"},{"key":"10.1002\/14651858.CD004246.pub3-BIB39|cit39","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/00126334-200103011-00004","article-title":"International perspectives on antiretroviral resistance","volume":"26 Suppl 1","author":"Deeks","year":"2001","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1002\/14651858.CD004246.pub3-BIB40|cit40","unstructured":"Department of Health and Human Sciences Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL04072005001.pdf.pages 58-63"},{"key":"10.1002\/14651858.CD004246.pub3-BIB41|cit41","unstructured":"Division of AIDS National Institute of Allergy and Infectious Diseases National Institutes of Health Table for Grading the Severity of Adult and Pediatric Adverse Events Bethesda, Maryland National Institutes of Health"},{"key":"10.1002\/14651858.CD004246.pub3-BIB42|cit42","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1258\/09564620360719840","article-title":"Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients","volume":"14","author":"Ena","year":"2003","journal-title":"International Journal of STD and AIDS"},{"issue":"1","key":"10.1002\/14651858.CD004246.pub3-BIB43|cit43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD004246.pub3-BIB44|cit44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2710.2008.00988.x","article-title":"A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India","volume":"34","author":"George","year":"2009","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1002\/14651858.CD004246.pub3-BIB45|cit45","first-page":"505","article-title":"The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings","volume":"368 (9534)","author":"Gilks","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004246.pub3-BIB46|cit46","unstructured":"Jan Bozek Andrew Oxman Olger Schunemann Gradepro 2008"},{"issue":"7650","key":"10.1002\/14651858.CD004246.pub3-BIB47|cit47","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"British Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD004246.pub3-BIB48|cit48","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel","volume":"300","author":"Hammer","year":"2008","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD004246.pub3-BIB49|cit49","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"10.1002\/14651858.CD004246.pub3-BIB50|cit50","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0140-6736(05)62505-6","article-title":"Decline in deaths from AIDS due to new antiretrovirals","volume":"349(9061)","author":"Hogg","year":"1997","journal-title":"Lancet"},{"issue":"1470","key":"10.1002\/14651858.CD004246.pub3-BIB51|cit51","first-page":"1503","article-title":"Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor : discrepancies between direct and indirect meta-analyses","volume":"368","author":"Ioannidis\u00a0JPA","year":"2006","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004246.pub3-BIB52|cit52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/135965350501000114","article-title":"Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study","volume":"10","author":"Kappelhoff","year":"2005","journal-title":"Antiviral Therapy"},{"key":"10.1002\/14651858.CD004246.pub3-BIB53|cit53","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/135965350501000404","article-title":"Are adverse events of nevirapine and efavirenz related to plasma concentrations","volume":"10","author":"Kappelhoff","year":"2005","journal-title":"Antiviral Therapy"},{"key":"10.1002\/14651858.CD004246.pub3-BIB54|cit54","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1310\/M47B-R51C-X0MC-K3GW","article-title":"Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-na\u00efve patients: a cohort study","volume":"3","author":"Keiser","year":"2002","journal-title":"HIV Clinical Trials"},{"key":"10.1002\/14651858.CD004246.pub3-BIB55|cit55","series-title":"14th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Predictive Value of Plasma HIV RNA Levels for Rate of CD4 Decline and Clinical Disease Progression","author":"Lau"},{"key":"10.1002\/14651858.CD004246.pub3-BIB56|cit56","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0197-2456(01)00111-8","article-title":"The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial","volume":"22","author":"MacArthur","year":"2001","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD004246.pub3-BIB57|cit57","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1468-1293.2008.00563.x","article-title":"Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin","volume":"9","author":"Manosuthi","year":"2008","journal-title":"HIV Medicine"},{"key":"10.1002\/14651858.CD004246.pub3-BIB58|cit58","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1310\/N4VT-3E9U-4BKN-CRPW","article-title":"Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine","volume":"4","author":"Mart\u00edn-Carbonero","year":"2003","journal-title":"HIV Clinical Trials"},{"key":"10.1002\/14651858.CD004246.pub3-BIB59|cit59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00002030-200201040-00008","article-title":"Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study","volume":"16","author":"Matthews","year":"2002","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD004246.pub3-BIB60|cit60","series-title":"14th Conference on Retroviruses and Opportunistic Infections","article-title":"Comparison of plasma HIV-1 RNA, CD4 Cell Count, and CD38 Expression on CD8 T cells as predictors of progression to AIDS and CD4 cell decline among untreated participants in the multicenter AIDS cohort study","author":"Mellors"},{"key":"10.1002\/14651858.CD004246.pub3-BIB61|cit61","first-page":"1725","article-title":"Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group","volume":"28;352(9142)","author":"Mocroft","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD004246.pub3-BIB62|cit62","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00001432-200002000-00004","article-title":"Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection","volume":"13","author":"Moyle","year":"2000","journal-title":"Current Opinion in Infectious Diseases"},{"key":"10.1002\/14651858.CD004246.pub3-BIB63|cit63","series-title":"2nd International AIDS Society Conference on HIV Pathogenesis and Treatment","article-title":"Systematic review of nevirapine versus efavirenz- containing three-drug regimens for initial treatment of HIV infection","author":"Neuwelt"},{"issue":"13","key":"10.1002\/14651858.CD004246.pub3-BIB64|cit64","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"Palella","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004246.pub3-BIB65|cit65","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00126334-200204010-00003","article-title":"Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors","volume":"29","author":"Palmon","year":"2002","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1002\/14651858.CD004246.pub3-BIB66|cit66","first-page":"915","article-title":"Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort","volume":"54","author":"Patel","year":"2006","journal-title":"The Journal of the Association of Physicians of India"},{"key":"10.1002\/14651858.CD004246.pub3-BIB67|cit67","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/428093","article-title":"Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects","volume":"191","author":"Sanne","year":"2005","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD004246.pub3-BIB68|cit68","first-page":"360","article-title":"Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana","volume":"13","author":"Shipton","year":"2009","journal-title":"The International Journal of Tubercosis and Lung Disease: the official publication of the International Union against Tuberculosis and Lung Disease"},{"issue":"2","key":"10.1002\/14651858.CD004246.pub3-BIB69|cit69","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004535.pub2","article-title":"Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults","author":"Siegfried","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004246.pub3-BIB70|cit70","unstructured":"Report on the global HIV\/AIDS epidemic 2008 UNAIDS\/08.27E \/ JC1511E"},{"key":"10.1002\/14651858.CD004246.pub3-BIB71|cit71","unstructured":"UNAIDS 2009 Report on global AIDS epidemic http:\/\/data.unaids.org\/pub\/Report\/2009\/2009_epidemic_update_en.pdf."},{"key":"10.1002\/14651858.CD004246.pub3-BIB72|cit72","series-title":"XVI International AIDS Conference","article-title":"Efficacy and safety of nevirapine versus efavirenz when combined in ART regimens in HIV-infectedantiretroviral-na\u00efve persons (the NNRTI sub study of FIRST-CPCRA 058)","author":"Berg-Wolf"},{"key":"10.1002\/14651858.CD004246.pub3-BIB73|cit73","series-title":"11th Conference on Retroviruses and Opportunistic infections (CROI); 2004 Feb 8-11","article-title":"Virologic failure in antiretroviral therapy naive patients Is only determined by extreme low values of CD4+ cells or high values of HIV-1 RNA concentration, not by choice of treatment with nevirapine or efavirenz","author":"Leth","year":"2004"},{"key":"10.1002\/14651858.CD004246.pub3-BIB74|cit74","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/135965350400900512","article-title":"Qualityof life in patients treated with first-line antiretroviral therapy containing nevirapine and\/or efavirenz","volume":"9","author":"Leth","year":"2004","journal-title":"Antiviral Therapy"},{"issue":"1","key":"10.1002\/14651858.CD004246.pub3-BIB75|cit75","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1371\/journal.pmed.0010019","article-title":"Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1","volume":"1","author":"Leth","year":"2004","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD004246.pub3-BIB76|cit76","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.aids.0000162334.12815.5b","article-title":"The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART","volume":"19","author":"Leth","year":"2005","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD004246.pub3-BIB77|cit77","first-page":"296","article-title":"Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine,efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN sub study","volume":"38","author":"Leth","year":"2005","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1002\/14651858.CD004246.pub3-BIB78|cit78","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1468-1293.2006.00390.x","article-title":"Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine","volume":"7","author":"Leth","year":"2006","journal-title":"HIV Medicines"},{"key":"10.1002\/14651858.CD004246.pub3-BIB79|cit79","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1089\/aid.2006.22.232","article-title":"Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy","volume":"22","author":"Leth","year":"2006","journal-title":"AIDS Research and Human Retroviruses"},{"key":"10.1002\/14651858.CD004246.pub3-BIB80|cit80","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2334-9-42","article-title":"HIV care and treatment factors associated with survival duringTB treatment in Thailand: an observational study","volume":"9","author":"Varma","year":"2009","journal-title":"BMC Infectious Diseases"},{"key":"10.1002\/14651858.CD004246.pub3-BIB81|cit81","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/00002030-200106150-00003","article-title":"High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals","volume":"15","author":"Veldkamp","year":"2001","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD004246.pub3-BIB82|cit82","article-title":"Scaling up antiretroviral therapy in low in resource-limited settings. Guidelines for a public health approach","author":"WHO","year":"2002","journal-title":"World Health Organisation, Geneva, Switzerland"},{"key":"10.1002\/14651858.CD004246.pub3-BIB83|cit83","unstructured":"WHO Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2006 revision http:\/\/whqlibdoc.who.int\/publications\/2006\/9789241594677_eng.pdf page 28"},{"key":"10.1002\/14651858.CD004246.pub3-BIB84|cit84","unstructured":"WHO WHO Model List of Essential Medicines. 15th List http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/index.html"},{"key":"10.1002\/14651858.CD004246.pub3-BIB85|cit85","unstructured":"WHO Rapid advice: Antiretroviral therapy for HIV infection in adults and adolescents World Health Organisation, Geneva, Switzerland 2009"}],"updated-by":[{"DOI":"10.1002\/14651858.cd004246.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T00:00:00Z","timestamp":1481328000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD004246.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T09:31:59Z","timestamp":1685871119000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD004246.pub3"}},"subtitle":[],"editor":[{"given":"Lawrence CE","family":"Mbuagbaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,12,8]]},"references-count":85,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004246.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD004246.pub4","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2010,12,8]]}}}